Baillie Gifford - LYELL IMMUNOPHARMA INC ownership

LYELL IMMUNOPHARMA INC's ticker is LYEL and the CUSIP is 55083R104. A total of 95 filers reported holding LYELL IMMUNOPHARMA INC in Q4 2022. The put-call ratio across all filers is 0.74 and the average weighting 0.9%.

Quarter-by-quarter ownership
Baillie Gifford ownership history of LYELL IMMUNOPHARMA INC
ValueSharesWeighting
Q3 2023$1,076,975
-55.5%
732,636
-3.8%
0.00%
-50.0%
Q2 2023$2,421,001
+34.7%
761,3210.0%0.00%0.0%
Q1 2023$1,796,718
-32.0%
761,3210.0%0.00%
-33.3%
Q4 2022$2,641,784
-52.3%
761,321
+0.8%
0.00%
-50.0%
Q3 2022$5,535,000
+19.9%
755,105
+6.7%
0.01%
+20.0%
Q2 2022$4,615,000
+16.5%
707,665
-9.8%
0.01%
+66.7%
Q1 2022$3,963,000
-29.2%
784,741
+8.5%
0.00%0.0%
Q4 2021$5,599,000
-11.5%
723,370
+69.2%
0.00%0.0%
Q3 2021$6,327,000
+50.5%
427,483
+65.2%
0.00%
+50.0%
Q2 2021$4,204,000258,8230.00%
Other shareholders
LYELL IMMUNOPHARMA INC shareholders Q4 2022
NameSharesValueWeighting ↓
MWG Management Ltd. 20,162,332$69,963,29235.72%
Orland Properties Ltd 15,093,969$52,376,07227.91%
Foresite Capital Management IV, LLC 10,000,000$34,700,00014.82%
MIC Capital Management UK LLP 3,060,569$10,620,1742.10%
Alphabet Inc. 5,865,125$20,351,9841.18%
HSG Holding Ltd 3,045,997$10,569,6101.07%
Artal Group S.A. 700,000$2,4290.14%
Eagle Health Investments LP 100,000$347,0000.08%
Virtus ETF Advisers LLC 39,345$136,5270.07%
BBR PARTNERS, LLC 164,041$569,2220.06%
View complete list of LYELL IMMUNOPHARMA INC shareholders